Braeburn Patent-Cliff Exposure & CMS Drug Spending Portfolio

Braeburn (US): 1 reconciled FDA prescription therapies, $126.4M 2024 CMS Part D & Medicaid spend, and $1,595 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$126.4M
2024 Medicare Part D Spend$11.2M
2024 Medicaid Spend$115.2M
California HCAI SB 17 FilingsSpecialty launch notice ($1,595 intro WAC)